A Phase 1, open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibility and safety of intratumoral injection with or without intramural injection in subjects with bladder cancer (CTMS#22-0121)
Lay Description
Category
- Cancers and Other Neoplasms
- Urinary Tract and Kidney
- IRB Number
- 20230792HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Not set
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Brandi Weaver
(210) 567-0158
weaverb@uthscsa.edu
Principal Investigator
Ahmed Mansour Elkenany